A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorInventisBio Co., Ltd
About this trial
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase, where those on 27 mg or placebo will switch to one of the lower doses.
All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
Eligibility criteria
Qualifiers
Voluntarily signs informed consent and complies with study procedures.
Age 18-65 years, male or female.
Clinical diagnosis of non-segmental vitiligo at screening.
F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.
Disqualifiers
- Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment.
Over 33% facial or total vitiligo lesions with leukotrichia.
Pregnant or breastfeeding females.
Active, latent or inadequately treated tuberculosis infection.
Trial design
Treatments tested in this trial
- D-2570 9mg
- D-2570 18mg
- Placebo
- D-2570 27mg
Treatment groups
160 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov